These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15079762)

  • 1. Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behçet disease: results of an open 4-center trial.
    Kötter I; Vonthein R; Zierhut M; Eckstein AK; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Stübiger N
    Semin Arthritis Rheum; 2004 Apr; 33(5):311-9. PubMed ID: 15079762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.
    Kötter I; Zierhut M; Eckstein AK; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Meyer-Riemann W; Peter HH; Stübiger N
    Br J Ophthalmol; 2003 Apr; 87(4):423-31. PubMed ID: 12642304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Behçet's disease: uveitis-therapy with interferon alpha2a - prospective clinical study in 33 patients].
    Stübiger N; Kötter I; Deuter C; Zierhut M
    Klin Monbl Augenheilkd; 2001 Dec; 218(12):768-73. PubMed ID: 11805868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Experience of Interferon Alfa-2a Treatment for Refractory Uveitis in Behçet's Disease.
    Park JY; Chung YR; Lee K; Song JH; Lee ES
    Yonsei Med J; 2015 Jul; 56(4):1158-62. PubMed ID: 26069144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behçet disease.
    Gueudry J; Wechsler B; Terrada C; Gendron G; Cassoux N; Fardeau C; Lehoang P; Piette JC; Bodaghi B
    Am J Ophthalmol; 2008 Dec; 146(6):837-44.e1. PubMed ID: 19027420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-interferon alpha antibodies and autoantibodies in patients with Behçet's disease uveitis treated with recombinant human interferon alpha-2a.
    Aydinoglu-Candan Ö; Araz-Erşan B; Gul A; Badur S; Tugal-Tutkun I
    Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):457-65. PubMed ID: 25500983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of Adamantiades-Behçet disease with systemic interferon alfa.
    Zouboulis CC; Orfanos CE
    Arch Dermatol; 1998 Aug; 134(8):1010-6. PubMed ID: 9722733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon-alpha--a new therapeutic option in refractory juvenile Behçet's disease with CNS involvement.
    Kuemmerle-Deschner JB; Tzaribachev N; Deuter C; Zierhut M; Batra M; Koetter I
    Rheumatology (Oxford); 2008 Jul; 47(7):1051-3. PubMed ID: 18492711
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ocular involvement in Behçet's disease: first 5-year-results for visual development after treatment with interferon alfa-2a].
    Deuter CM; Kötter I; Günaydin I; Zierhut M; Stübiger N
    Ophthalmologe; 2004 Feb; 101(2):129-34. PubMed ID: 14991308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human recombinant interferon-alpha2a (rhIFN alpha2a) for the treatment of Behçet's disease with sight-threatening retinal vasculitis.
    Kötter I; Zierhut M; Eckstein A; Vonthein R; Ness T; Günaydin I; Grimbacher B; Blaschke S; Peter HH; Kanz L; Stübiger N
    Adv Exp Med Biol; 2003; 528():521-3. PubMed ID: 12918755
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients.
    Bodaghi B; Gendron G; Wechsler B; Terrada C; Cassoux N; Huong du LT; Lemaitre C; Fradeau C; LeHoang P; Piette JC
    Br J Ophthalmol; 2007 Mar; 91(3):335-9. PubMed ID: 17050581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of interferon alpha-2a therapy in patients with Behcet's disease.
    Yalçindağ FN; Uzun A
    J Ocul Pharmacol Ther; 2012 Aug; 28(4):439-43. PubMed ID: 22455657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature.
    Kötter I; Koch S; Vonthein R; Rückwaldt U; Amberger M; Günaydin I; Zierhut M; Stübiger N
    Clin Exp Rheumatol; 2005; 23(4 Suppl 38):S20-6. PubMed ID: 16273760
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of interferon alpha in Behçet disease: review of the literature.
    Kötter I; Günaydin I; Zierhut M; Stübiger N
    Semin Arthritis Rheum; 2004 Apr; 33(5):320-35. PubMed ID: 15079763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of human recombinant interferon-alpha2a (rhIFN-alpha2a) on altered lymphocyte subpopulations and monocytes in Behcet's disease.
    Treusch M; Vonthein R; Baur M; Günaydin I; Koch S; Stübiger N; Eckstein AK; Peter HH; Ness T; Zierhut M; Kötter I
    Rheumatology (Oxford); 2004 Oct; 43(10):1275-82. PubMed ID: 15252211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet's uveitis refractory to conventional treatments.
    Sobaci G; Erdem U; Durukan AH; Erdurman C; Bayer A; Köksal S; Karagul S; Bayraktar MZ
    Ophthalmology; 2010 Jul; 117(7):1430-5. PubMed ID: 20417563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease.
    Wechsler B; Bodaghi B; Huong DL; Fardeau C; Amoura Z; Cassoux N; Piette JC; LeHoang P
    Ocul Immunol Inflamm; 2000 Dec; 8(4):293-301. PubMed ID: 11262659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
    Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
    Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.
    Kötter I; Eckstein AK; Stübiger N; Zierhut M
    Br J Ophthalmol; 1998 May; 82(5):488-94. PubMed ID: 9713053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-Term Efficacy of Pegylated Interferon Alpha-2b in Behçet's Uveitis: A Small Case Series.
    Celiker H; Kazokoglu H; Direskeneli H
    Ocul Immunol Inflamm; 2019; 27(1):15-22. PubMed ID: 28700247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.